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The studies on the association between serum cholesterol level and the risks of neurodegenerative diseases risk are debated. Some
prospective studies have found that high serum cholesterol may increase the risks of dementia/Alzheimer’s disease and ischemic
stroke. However, other studies have found no association or a decreased risk of hemorrhagic stroke with increasing levels of
serum total cholesterol. Little is known about the association between serum total cholesterol or a history of hypercholesterolemia
and Parkinson’s disease (PD) risk. Only a few case-control studies and four prospective epidemiological studies have examined
this association, but the results are inconsistent. An inverse association between serum total cholesterol and the risk of PD has
been found in one prospective study; however, no signiﬁcant association is reported in the case-control studies and other two
prospective studies. Recently, one large prospective study from Finland suggests that high total cholesterol at baseline is associated
with an increased risk of PD. Further studies, especially large clinical trials, are needed.
1. Parkinson’sDisease
Parkinson’s disease (PD) is the second most common
neurodegenerative disease of the elderly [1]. PD is a debil-
itating disorder manifested by bradykinesia, resting tremor,
muscular rigidity, gait disturbances, and postural reﬂex
impairment [1]. The underlying pathologic lesion is the
loss of the pigmented neurons of the substantia nigra, and
selected brain stem dopaminergic cell groups. However, the
causes of PD are not well known. The loss of substantia
nigra neurons results in depletion of the neurotransmitter
dopamine in these areas. There is evidence that genetic
f a c t o r sp l a yak e yr o l ei nd e v e l o p m e n to fP D[ 2, 3]. Studies
of twins have provided strong evidence for an important
role of environmental factors in the etiology of typical PD
[2]. The development of PD involves an interaction between
genes and environmental factors [2]. Thus, its prevention is
likely to be at least partly possible. In order to determine
interventions that would prevent or delay the onset of PD,
modiﬁable risk factors for the disease have to be identiﬁed
ﬁrst. These risk factors could then be used as targets for
intervention, and also population-based health education
and intervention programs could be developed. Because
the process leading to the clinical manifestation of PD
t a k e sd e c a d e s ,l o n g - t e r mp r o s p e c t i v es t u d i e sa r en e c e s s a r yt o
identify its environmental risk factors.
2.SerumTotal Cholesterol
Cholesterol is a lipid found in the cell membranes of all
animal tissues and is transported in the blood plasma of
all animals. Most of the cholesterol is synthesized by the
body and some have dietary origin. Cholesterol is more
abundant in tissues which either synthesize more or have
more abundant densely-packed membranes, for example,
the liver, spinal cord, and brain. It plays a central role in
many biochemical processes, such as the composition of cell
membranes and the synthesis of steroid hormones.
There is good evidence that high serum total cholesterol
level increases coronary heart disease risk in both middle-
andold-agedpeopleandinpeopleatallbloodpressurelevels
[4].However,theassociationbetweenserumcholesterollevel
andseveralneurodegenerativediseaseriskshasbeendebated.2 Parkinson’s Disease
S o m ep r o s p e c t i v es t u d i e sh a v ef o u n dt h a th i g hs e r u m
cholesterol may increase the risks of dementia/Alzheimer’s
disease [5, 6] and ischemic stroke [4]. Other studies have
found no association [7]o rad e c r e a s e dr i s ko fh e m o r r h a g i c
stroke with increasing levels of serum total cholesterol [4]. In
addition,littleisknownabouttheassociationbetweenserum
total cholesterol or a history of hypercholesterolemia and PD
risk.
3.SerumTotal Cholesterol andthe Risk of PD
Until now, only four case-control studies [8–11]a n df o u r
prospective epidemiological studies [12, 14–16] have exam-
ined the association between serum total cholesterol or a
history of hypercholesterolemia and the risk of PD, but the
results are inconsistent (Table 1).
3.1. Results from Case-Control Studies. In two small case-
control studies, serum total cholesterol did not diﬀer signif-
icantly between PD patients and controls [8, 9]( Table 1).
In one large retrospective case-control study including 178
newly diagnosed consecutive idiopathic PD patients and 533
age- and sex-matched controls, the investigators did not
ﬁnd any association between serum total cholesterol and
the occurrence of idiopathic PD [10]. In one recent case-
control study including 124 PD cases and 112 controls,
serum total cholesterol did not diﬀer signiﬁcantly between
PD patients and controls; however, use of cholesterol-
loweringdrugsinthispopulationwasassociatedwithalower
occurrence of PD, the odd ratio was 0.36 (95% CI 0.19–
0.68) after adjusting for age, gender, and smoking status
[11].Moreover,itindicatedthatlowerconcentrationsoflow-
density lipoprotein (LDL) cholesterol were associated with
higher occurrence of PD [11]; however, serum high-density
lipoprotein (HDL) cholesterol did not diﬀer signiﬁcantly
between PD patients and controls [11]. These case-control
studies indicate that serum total cholesterol did not diﬀer
signiﬁcantly between PD patients and controls.
3.2. Results from Prospective Studies. The prospective asso-
ciation of serum total cholesterol or a history of hyper-
cholesterolemia with PD risk has been assessed recently
[12, 14–16]. In the Honolulu Heart Program including 8006
Japanese-American men in Hawaii identiﬁed 58 PD cases
during a 26-year followup [12], the original aim of this
study was to assess the association of cigarette smoking
with PD risk. The age adjusted relative risk of PD was 0.73
(95% CI 0.43–1.24) [12]. In an updated analysis from the
Honolulu Heart Program, an inverse association between
LDL cholesterol and PD risk was presented among 3233
subjects [13]. In the Rotterdam Study documenting 87
cases of PD among 6465 Netherlanders during an average
9.4 years of followup [14], higher levels of serum total
cholesterol were associated with a signiﬁcantly decreased risk
of PD (hazard ratio 0.77, 95% CI 0.64–0.94 per 1.0mmol/L
increase in serum total cholesterol). In the further analyses,
the age- and sex-adjusted hazard ratios of incident PD across
quartiles of serum total cholesterol were 1.0, 0.82 (95% CI
0.48–1.41), 0.55 (95% CI 0.30–1.02), and 0.55 (95% CI
0.30–1.04), respectively [14]. With the pooled data from
Harvard, the Health Professionals Follow-up Study involved
50833 men identiﬁed 266 PD cases, and the Nurses’ Health
Study involved 121046 women identiﬁed 264 PD cases
during followup [15]. The history of physician-diagnosed
high cholesterol was collected by questionnaire. Age- and
smoking-adjusted relative risk of PD was not associated with
the baseline history of high cholesterol (relative risk 0.98,
95% CI 0.82–1.19) [15].
We evaluated prospectively the association between
serum total cholesterol and the risk of incident PD among
24773 Finnish men and 26153 women of 25 to 74 years
of age without a history of PD and stroke at baseline [16].
Serum total cholesterol was measured at baseline survey.
During a mean followup period of 18.1 years, 321 men
and 304 women developed incident PD. The multivariable-
adjusted (age, study year, body mass index, systolic blood
pressure, education, leisure time physical activity, smok-
ing, alcohol drinking, coﬀee and tea drinking, cholesterol-
lowering agent use, and the history of diabetes) hazard ratios
of incident PD at diﬀerent levels of total cholesterol (<5, 5–
5.9, 6–6.9, and ≥7mmol/L) were 1.00, 1.33, 1.53, and 1.84
(P for trend = .035) in men, 1.00, 1.55, 1.57, and 1.86 (P for
trend = .113) in women, and 1.00, 1.42, 1.56, and 1.86 (P for
trend = .002) in men and women combined (adjusted also
for sex) (Table 2). When total cholesterol was examined as
a continuous variable, multivariable-adjusted hazard ratios
of PD for each 1mmol/l increase in total cholesterol were
1.10 (95% CI 1.01–1.21) for men, 1.07 (95% CI 0.98–1.17)
for women, and 1.09 (95% CI 1.02–1.16) for men and
women combined (Table 1). After exclusion of participants
who used cholesterol-lowering agents (n = 371), sex- and
multivariate-adjusted hazard ratios of PD at diﬀerent levels
of total cholesterol (<5, 5–5.9, 6–6.9, and ≥7mmol/l) were 1,
1.42 (95% CI 0.99–2.02), 1.54 (95% CI 1.09–2.18), and 1.85
(95% CI 1.30–2.61) (P for trend = .002) [16].
In the multivariate analyses, the increased risk of PD
associated with increasing levels of total cholesterol was
present both in subjects aged 25–44 years (P for trend =
.025) and 45–54 years (P for trend = .011) at baseline, and in
never smokers (P for trend = .061) and smokers (P for trend
= .044), however, no association was found among subjects
aged55yearsormoreatbaseline(P fortrend =.98)(Table 2)
[16].
To our knowledge, this Finnish study is the ﬁrst large
prospective study to ﬁnd out that high total cholesterol
may increase PD risk. However, no signiﬁcant association
is reported by the case-control studies and other two
prospective studies, and an inverse association has been
f o u n di no n ep r o s p e c t i v es t u d y .S e v e r a lr e a s o n sf o rt h e
inconsistency of these studies can be considered. First,
potential bias in the case of PD could be substantial in these
case-control studies [8–11]. Second, an older age at baseline
in the Rotterdam Study (over 55 years) [14] could also be
considered since the association between total cholesterol
and the risk of PD in Finnish elder study samples (55–
74 years) was not signiﬁcant either [16]. Third, cholesterol
levels seem to decline with the development of manyParkinson’s Disease 3
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Table 2: Hazard ratio (HR) of Parkinson disease according to diﬀerent levels of total cholesterol among various subpopulations [16]∗.
HR (95% CI) Total cholesterol (mmol/L) P for trend
<5 5–5.9 6–6.9 ≥7.0
Total samples 1.00 1.42 (1.00–2.03) 1.56 (1.10–2.21) 1.86 (1.31–2.63) .002
Gender
Men 1.00 1.33 (0.81–2.16) 1.53 (0.96–2.46) 1.84 (1.14–2.95) .035
Women 1.00 1.55 (0.92–2.61) 1.57 (0.93–2.64) 1.86 (1.11–3.13) .113
Age (years)
25–44 1.00 1.90 (1.05–3.45) 1.79 (0.97–3.30) 2.54 (1.37–4.70) .025
45–54 1.00 1.34 (0.67–2.67) 1.65 (0.85–3.20) 2.20 (1.14–4.24) .011
55–74 1.00 1.00 (0.56–1.79) 1.07 (0.61–1.88) 1.03 (0.59–1.81) .98
Smoking
Never 1.00 1.34 (0.85–2.12) 1.57 (1.01–2.45) 1.74 (1.11–2.71) .061
Ever or current 1.00 1.58 (0.89–2.79) 1.55 (0.88–2.72) 2.05 (1.18–3.59) .044
∗Adjusted for age, sex (exception in gender analyses), study year, body mass index, systolic blood pressure, education, leisure-time physical activity, smoking
(except in smoking status analysis), coﬀee, tea, and alcohol consumption, cholesterol-lowering agent use, and history of diabetes.
chronic diseases including neurodegenerative disorders like
Alzheimer’s disease [17] before the clinical manifestation
of the disease. Previous results from the Finnish study
indicate that high mid-life serum total cholesterol is a
risk factor for subsequent dementia/Alzheimer’s disease [6],
and that decreased serum total cholesterol after mid-life
may reﬂect ongoing disease processes and may represent a
risk marker for dementia/Alzheimer’s disease [17]. Further
studies are needed to conﬁrm whether this is also true for
PD. Fourth, the history of high cholesterol was assessed
by questionnaire and no available data measured serum
total cholesterol in the Health Professionals Follow-up Study
and the Nurses’ Health Study making the data vulnerable
to various biases [15]. Fifth, few PD cases in these two
prospective studies may limit the statistical power [12, 14].
Sixth, since ascertainment of the PD cases in Finnish study
was based on the National Social Insurance Institution’s
Register on special reimbursement for PD drugs, people
with high total cholesterol level are more prone to other
diseases and therefore are likely to be in contact with the
health care system more often than people with normal total
cholesterol. This could not be easily justiﬁed and may result
in an ascertainment bias [16]. However, we think this is less
likely for PD, because PD symptoms are clearly deﬁned, and
likelytobringasubjecttotheattentionofthemedicalsystem
[16].
4.Biological Mechanisms
Even though the Finnish study ﬁnds an increased PD risk
associated with high levels of total cholesterol, the mech-
anisms of this association are poorly understood. Several
putative mechanisms may be proposed. This association may
however not be completely unexpected given that brain is
the most cholesterol rich organ in the whole body; distur-
bances in cholesterol homeostasis may therefore inﬂuence
the structure, function, and maintenance of neuronal cell
membranes and synapses [18]. The aggregation of alfa-
synuclein is believed to play a critical role in the pathogenesis
of PD. Interestingly, recent data indicate that change in
cholesterol composition using cholesterol-lowering agents
reduces the levels of alfa-synuclein in vitro [19]. Alfa-
synuclein is also known to inﬂuence brain lipid metabolism
[20]. The epidemiologic studies have shown that high
serum cholesterol is associated with an increased risk of
dementia/Alzheimer’s disease [5, 6], and statins may delay
the progression of Alzheimer’s disease and PD [11, 21]. For
the inverse association between serum total cholesterol and
the PD risk in the Rotterdam Study [14], they proposed that
the strong correlation between levels of serum cholesterol
and the antioxidant coenzyme Q10 may support for of
oxidative stress in the pathogenesis of Parkinson’s disease.
It could also be hypothesized that high total cholesterol
might increase the risk of PD partly through excess body
weight. The results from the Honolulu Heart Program and
our study have demonstrated that excess weight is associated
with an elevated PD risk [22, 23]. In the Finnish study, there
was a positive association between BMI and serum total
cholesterol [16]. However, the positive association of total
cholesterol with PD risk in Finnish study was independent
of baseline BMI [16]. A decreased PD risk associated with
an increased leisure-time physical activity level has been
found among men in the Health Professionals Follow-up
Study but not among women in the Nurses’ Health Study
[24]. Recently, The Finnish study also found that a history
of diabetes was associated with an increased risk of PD
[25]. However, taking into account these possible eﬀects by
adjusting for baseline habits of leisure-time physical activity,
coﬀee consumption [26], history of diabetes, and other risk
factors[27]includingbaselinesystolicbloodpressuredidnot
change the positive association of total cholesterol and the
risk of PD in the Finnish Study [16].
Results from case-control studies have suggested an
association between PD and dietary factors, such as total,
saturated, and animal fat intake and energy intake [28, 29],
but the results from prospective studies are conﬂicting. In
Honolulu Heart Program among Japanese-American men,
no association between diet and the risk of PD was seen [23].Parkinson’s Disease 5
In the Health Professionals Follow-up Study and the Nurses’
Health Study, higher baseline intakes of animal fat and
saturated fat tended to increase the risk of PD in men (P = .1
for trend) but not in women [30]. It could be hypothesized
that high serum total cholesterol might increase the risk of
PD partly through dietary factors.
5. Conclusions
The studies on the association between serum total choles-
terol and a history of hypercholesterolemia and the risk
of PD are few the results are inconsistent. A decreased
risk of PD with higher serum levels of total cholesterol
has been found in one prospective study; however, no
signiﬁcant association is reported in the case-control studies
andothertwoprospectivestudies.Theresultfromonerecent
large Finnish prospective study has shown that high total
cholesterol at baseline is associated with an increased risk
of PD. This increased risk of PD associated with increasing
levels of serum total cholesterol was present both in subjects
aged 25–44 years and 45–54 years at baseline, and no
association was found among subjects aged 55 years or
more at baseline. Since most above studies only had baseline
measurement of total cholesterol and changes in the levels of
total cholesterol were not available during followup, further
studies, especially large clinical trials, are needed in the next
several years. It would be important to ﬁnd out mechanisms
behind the association between serum total cholesterol and
PD risk.
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